CryoPort, Inc. to Exhibit at Drug Information Association's 44th Annual Meeting

LAKE FOREST, CA -- (MARKET WIRE) -- 06/20/08 -- CryoPort, Inc. (OTCBB: CYRX), a leading developer of shipping technologies for the biopharmaceutical cold-chain shipping industry, today announced that it will be exhibiting at the 44th Annual Meeting of the Drug Information Association (DIA) being held in Boston on June 22-26, 2008.

The Company will be in booth 1934. The DIA serves more than 30,000 professionals involved in the discovery, development, regulation, surveillance, or marketing of pharmaceuticals or related products worldwide.

CryoPort CEO, Peter Berry, said, "The DIA Conference is an excellent venue to meet with high level individuals who are directly involved in the decision-making process. Many potential end-users of our CryoPort Express(TM) Shipper will be in attendance providing us an opportunity to show the value and benefit of our product on a one-on-one basis. "

To be added to CryoPort's investor list, please email:

About CryoPort, Inc.

CryoPort ( develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold shipping chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.


This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Stuart Fine
Carpe DM, Inc.